SFX-01 is under clinical development by Stalicla and currently in Phase I for Glioma. According to GlobalData, Phase I drugs for Glioma have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how SFX-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SFX-01 overview

SFX-01 is under development for the treatment of estrogen receptor (er) positive and human epidermal growth factor receptor 2 (her2) negative metastatic breast cancer, cerebral vasospasm, the incidence of delayed cerebral ischemia, prostate cancer, glioblastoma, juvenile myelomonocytic leukaemia (JMML), idiopathic pulmonary fibrosis, glioma, breast cancer, multiple sclerosis, osteoarthritis, osteoporosis, autism spectrum disorder, Parkinson's disease, malignant glioma, colorectal cancer and non-alcoholic fatty liver disease (NAFLD). It is administered orally. The drug candidate is a stabilized synthetic version of sulforaphane. The drug candidate acts by targeting the mutated kelch like ECH associated protein 1 (KEAP1).

It was also under development for the treatment of chronic obstructive pulmonary disease (COPD), acute lymphoblastic leukemia (ALL), acute myelocytic leukemia, subarachnoid hemorrhage,community acquired pneumonia and acute respiratory distress syndrome associated with COVID-19 and cardiovascular diseases.

Stalicla overview

Stalicla is a biotechnology company developing precision medicine treatments for patients with Neurodevelopmental disorders. Stalicla is headquartered in Geneva, Switzerland.

For a complete picture of SFX-01’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.